Early last week we sold Pfizer across all accounts invested in our dividend growth strategy.* We initially invested in Pfizer because it was undervalued, had an above average dividend yield, was growing its dividend, and it looked like the company… Read More
AMM Dividend Letter Issue 28: How to Beat a Pigeon at Investing with Pfizer (PFE)
This is from the AMM Dividend Letter released April 7, 2016. If you want to see the latest “Dividend Stock in Focus” as soon as it’s released then join our mailing list here. This is the competition. It’s you versus… Read More
Pfizer, A Cheap Stock with a 3% Yield
We’re always big fans of confirmation bias. Today’s confirmation bias comes from Barron’s. They ran a screen for companies with dividend yields greater than the S&P 500’s current yield and with increasing earnings estimates. Barron’s came up with 4 and… Read More